ALX Oncology
Latest round
- Series C
Last raised
- Feb 2020
Total raised
- $141M
Investors
- 11
About ALX Oncology
Founded in 2015 and headquartered in Burlingame, US, ALX Oncology Limited specializes in creating innovative therapies for oncology. The company was established by Kipp Weiskopf.ALX Oncology primarily focuses on developing innovative immuno-oncology therapies aimed at enhancing the body’s immune response to cancer. Their lead product, evorpacept, is designed to optimize the current treatment landscape by serving as a cornerstone therapy for various cancer types. This therapeutic candidate has undergone clinical validation, showcasing its potential to improve patient outcomes by boosting immune system functionality against tumors. The company targets a diverse patient population, particularly those battling various forms of cancer across multiple geographical markets, including North America, Europe, and Asia.In 2020, ALX Oncology reported revenue of USD 1,182,000 and an EBITDA loss of USD 141,595,000 for the same year. Their revenue generation operates primarily through clinical partnerships and collaborations with pharmaceutical companies and research institutions, focused on advancing their flagship product, evorpacept.ALX Oncology's strategy for future growth includes the development of ALX148, a next-generation CD47 myeloid checkpoint inhibitor, which is being designed for use in combination with anti-cancer therapeutics. The company aims to expand its offerings into additional solid tumors and hematologic indications. ALX Oncology plans to leverage these resources to enhance their product pipeline and improve access to new markets.
Who invested in ALX Oncology
11 investors across 2 rounds
See all investors in ALX Oncology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ALX Oncology
Who invested in ALX Oncology?
ALX Oncology has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ALX Oncology raised?
ALX Oncology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ALX Oncology last raise money?
ALX Oncology's most recent round on record is a Series C, in Feb 2020.
What does ALX Oncology do?
Founded in 2015 and headquartered in Burlingame, US, ALX Oncology Limited specializes in creating innovative therapies for oncology.
Where is ALX Oncology headquartered?
ALX Oncology is headquartered in Burlingame, US.
Which VCs invest in companies like ALX Oncology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ALX Oncology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like ALX Oncology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.